Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker TestingGlobeNewsWire • 12/11/19
High Growth Non-Invasive Cancer Test Technology: Guardant Health Vs. Exact SciencesSeeking Alpha • 12/02/19
Guardant Health Inc (GH) CEO Helmy Eltoukhy on Q3 2019 - Earnings Call TranscriptSeeking Alpha • 11/08/19
Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted TherapyGlobeNewsWire • 09/28/19
Guardant Health Inc (GH) Chairman, President and COO Amirali Talasaz Sold $5.1 million of SharesGuruFocus • 08/26/19